Skip to main content

Table 1 Demographic and clinical characteristics of patients with stages I–II and III–IV pancreatic cancer

From: Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study

Parameter USA (2004–2013) The Netherlands (2003–2014) Belgium (2004–2013) Norway (2003–2014) Slovenia (2003–2013)
Group Overall Resected Overall Resected Overall Resected Overall Resected Overall Resected
Stages I–II
Number (n) 31,313 13,303 (43) 5710 2675 (47) 3437 2155 (63) 1545 526 (34) 667 406 (61)
Microscopically confirmed 27,290 (87) 13,290 (> 99) 4046 (71) 2673 (> 99) 3127 (91) 2148 (> 99) 1017 (66) 520 (99) 475 (71) 401 (99)
Gender, female 16,193 (52) 6604 (50) 2951 (52) 1268 (47) 1684 (49) 993 (46) 853 (55) 261 (50) 361 (54) 209 (52)
Age, years 70 ± 12 66 ± 11 71 ± 11 65 ± 10 69 ± 11 66 ± 10 72 ± 12 65 ± 11 69 ± 11 65 ± 10
Age group
  < 60 years 6100 (20) 3574 (27) 981 (17) 693 (26) 686 (20) 546 (25) 234 (15) 134 (26) 144 (22) 122 (30)
 60–69 years 7817 (25) 4272 (32) 1477 (26) 978 (37) 937 (27) 698 (32) 375 (24) 195 (37) 166 (25) 131 (32)
  ≥ 70 years 17,396 (56) 5457 (41) 3252 (57) 1004 (38) 1814 (53) 911 (42) 936 (61) 197 (37) 357 (54) 153 (38)
Tumor locationa
 Pancreas head 22,412 (83) 9573 (80) 4666 (89) 2187 (89) 1807 (81) 1207 (82) 851 (85) 394 (84) 471 (88) 321 (87)
 Pancreas body 2502 (9) 890 (8) 255 (5) 91 (4) 179 (8) 100 (7) 87 (9) 33 (7) 35 (7) 26 (7)
 Pancreas tail 2196 (8) 1448 (12) 296 (6) 191 (8) 244 (11) 169 (11) 62 (6) 41 (9) 32 (6) 21 (6)
 Other 4203 (13) 1392 (11) 493 (9) 206 (8) 1207 (35) 679 (32) 545 (35) 58 (11) 129 (19) 38 (9)
Differentiationb
 Well 2145 (13) 1428 (12) 283 (12) 244 (11) 389 (18) 302 (17) 61 (10) 27 (6) 41 (10) 37 (10)
 Intermediate 7574 (47) 6026 (51) 1225 (51) 1138 (52) 1072 (48) 901 (50) 352 (55) 259 (61) 153 (37) 142 (38)
 Poor/undifferentiated 6264 (39) 4464 (38) 920 (38) 802 (37) 762 (34) 608 (34) 223 (35) 135 (32) 221 (53) 192 (52)
Neoadjuvant chemotherapy – NA – 50 (2) – 53 (3) – NA – 2 (1)
Neoadjuvant radiotherapy – 522 (4) – 34 (1) – 20 (1) – 0 (0) – 1 (< 1)
Resection type
 Pancreatoduodenectomy – 9479 (71) – 2269 (85) – NA – NA – NA
 Distal pancreatectomy – 1878 (14) – 256 (10) – NA – NA – NA
 Total pancreatectomy – 1629 (12) – 42 (2) – NA – NA – NA
 Otherc – 314 (2) – 108 (4) – NA – NA – NA
Adjuvant/palliative chemotherapy NA NA 1392 (24) 1078 (40) 1796 (52) 1200 (56) 265 (17) 127 (24) 131 (20) 120 (30)
Adjuvant/palliative radiotherapy 4460 (14) 4193 (32) 120 (2) 33 (1) 326 (10) 190 (9) 64 (4) 17 (3) 9 (1) 8 (2)
Stages III–IV
Number (n) 55,153 1998 (4) 13,974 237 (2) 5632 298 (5) 4633 108 (2) 1997 135 (7)
Microscopically confirmed 46,973 (85) 1994 (> 99) 10,375 (74) 237 (100) 4837 (86) 297 (> 99) 3224 (70) 105 (97) 1056 (53) 124 (92)
Gender, female 26,427 (48) 969 (49) 6755 (48) 106 (45) 2700 (48) 154 (52) 2332 (50) 47 (44) 967 (48) 56 (42)
Age, years 69 ± 12 65 ± 12 68 ± 11 64 ± 10 69 ± 11 64 ± 10 71 ± 12 64 ± 10 69 ± 11 65 ± 10
Age group
  < 60 years 12,582 (23) 636 (32) 2938 (21) 69 (29) 1043 (19) 92 (31) 759 (16) 32 (30) 393 (20) 40 (30)
 60–69 years 15,081 (27) 622 (31) 4412 (32) 96 (41) 1608 (29) 103 (35) 1268 (27) 43 (40) 513 (26) 45 (33)
  ≥ 70 years 27,490 (50) 740 (37) 6624 (47) 72 (30) 2981 (53) 103 (35) 2606 (56) 26 (24) 1091 (55) 43 (32)
Tumor locationa
 Pancreas head 21,244 (56) 1069 (66) 7202 (62) 166 (79) 1585 (58) 126 (69) 1245 (63) 57 (66) 653 (64) 80 (78)
 Pancreas body 7893 (21) 168 (10) 1844 (16) 11 (5) 508 (19) 19 (10) 340 (17) 8 (9) 160 (16) 12 (12)
 Pancreas tail 9003 (24) 381 (24) 2666 (23) 34 (16) 649 (24) 37 (20) 382 (19) 21 (24) 215 (21) 10 (10)
 Other 17,013 (31) 380 (19) 2262 (16) 26 (11) 2890 (51) 116 (39) 2666 (58) 22 (20) 969 (49) 33 (24)
Differentiationd
 Well 1213 (10) 173 (11) 222 (9) 20 (11) 425 (17) 42 (17) 122 (8) 6 (7) 33 (8) 6 (7)
 Intermediate 4518 (35) 680 (45) 833 (35) 98 (51) 962 (39) 113 (47) 596 (40) 50 (61) 112 (25) 30 (34)
 Poor/undifferentiated 6795 (56) 670 (44) 1340 (56) 73 (38) 1082 (44) 88 (36) 765 (52) 26 (32) 297 (67) 52 (59)
Neoadjuvant chemotherapy – NA – 15 (6) – 24 (8) – NA – 0 (0)
Neoadjuvant radiotherapy – 139 (7) – 5 (2) – 9 (3) – 0 (0) – 0 (0)
Resection type
 Pancreatoduodenectomy – 1140 (57) – 178 (75) – NA – NA – NA
 Distal pancreatectomy – 295 (15) – 39 (17) – NA – NA – NA
 Total pancreatectomy – 211 (11) – 5 (2) – NA – NA – NA
 Otherc – 352 (18) – 15 (6) – NA – NA – NA
Adjuvant/palliative chemotherapy NA NA 3475 (25) 81 (34) 3661 (65) 195 (65) 1159 (25) 25 (23) 368 (18) 39 (29)
Adjuvant/palliative radiotherapy 770 (1) 383 (19) 328 (2) 7 (3) 358 (6) 35 (12) 198 (4) 4 (4) 46 (2) 5 (4)
  1. NOS not otherwise specified, NA not available; −, not applicable
  2. Enumeration data are shown as count (percentage [%]), and measurement data as mean ± standard deviation. Records are complete, otherwise specified below
  3. aThe percentages of pancreas head, body, and tail are the proportions compared to the total tumor cases of the 3 locations; ”other” includes pancreas duct, overlapping lesion, NOS, and other specified parts, and its proportion is relative to the whole cases
  4. bUnknown differentiation in stages I–II cancer: USA, overall 15,330 (49%), resected 1385 (10%); the Netherlands, overall 3282 (58%), resected 491 (18%); Belgium, overall 1214 (35%), resected 344 (16%); Norway, overall 909 (59%), resected 100 (19%); Slovenia, overall 252 (38%), resected 35 (9%); Estonia, overall 134 (47%), resected 32 (20%)
  5. cPancreatectomy (NOS) and local resection
  6. dUnknown differentiation in stages III–IV cancer: USA, overall 42,627 (77%), resected 475 (24%); the Netherlands, overall 11,579 (83%), resected 46 (19%); Belgium, overall 3163 (56%), resected 55 (19%); Norway, overall 3150 (68%), resected 26 (24%); Slovenia, overall 1555 (78%), resected 47 (35%); Estonia, overall 718 (86%), resected 5 (28%)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us